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Abstract
Associations of Raynaud’s phenomenon (RP) with venous thromboembolism (VTE) are unclear. We investigated the occur-
rence of RP together with prothrombotic state markers and fibrin clot properties in VTE patients. In this prospective cohort 
study we enrolled 360 patients free of known autoimmune disease. D-dimer, von Willebrand factor (vWF), plasma clot 
permeability  (Ks), clot lysis time (CLT) along with fibrinolysis activators and inhibitors were determined at least 3 months 
since the VTE event. The presence/absence of RP was diagnosed at least 6 months before VTE. Primary RP occurred in 57 
subjects (17%) with a 3.6-fold higher prevalence among women. Patients with RP had 11% higher fibrinogen, 16% higher 
vWF, 5% lower  Ks, and 10% longer CLT (all p < 0.05). Females with RP (21%) had 6.6% lower  Ks, 11.2% longer CLT, and 
18.5% higher vWF (all p < 0.05) compared with men. CLT was predicted by PAI-1 and vWF levels. Regression analysis 
showed that RP was a predictor of prolonged CLT in the whole patient group (OR 3.46, 95% CI 1.92–6.24) and in women 
following VTE (OR 2.75, 95% CI 1.31–5.78). Primary RP patients tend to form denser plasma fibrin clots displaying impaired 
lysability and increased endothelial damage. RP might be a novel risk factor for VTE, especially in women.
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Highlights
• Primary Raynaud’s phenomenon (RP) occurs relatively 
frequently among patients with venous thromboembo-
lism (VTE).
• Primary RP is associated with formation of denser fibrin 
clots less susceptible to lysis.
• Primary RP is associated with increased endothelial dam-
age.
• RP might be a novel risk factor for VTE, especially in 
women.
Introduction
Raynaud’s phenomenon (RP) is a vasospastic disorder usu-
ally involving peripheral small vessels of the fingers or toes 
in response to cold and/or emotional stress. This disorder 
is characterized by an episodic pallor, followed by cyano-
sis because of slow blood flow, and then rubor reflects the 
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reactive hyperaemic phase. Ischemia, de-oxygenation and 
hyperaemia are the sequence of a typical attack [1–4].
A prevalence of RP is estimated at 3–5% of the Cauca-
sian general population and it may be even higher in cold 
climates living populations [5]. RP is fourfold more common 
in women and more prevalent among individuals aged from 
20 to 60 years [6].
RP is categorized as primary (80% of patients) or sec-
ondary. The aetiology of primary RP is unclear, while 
secondary RP is associated with numerous condition [4]. 
RP is observed commonly in patients with systemic scle-
rosis (SSc), in particular those with calcinosis, Raynaud’s 
phenomenon, oesophageal dysmobility, sclerodactyly, tel-
angiectasia (CREST), however RP occurs frequently also 
in patients with mixed connective tissue disease, systemic 
lupus erythematosus, poly- or dermatomyositis, and other 
systemic autoimmune diseases [6]. RP is also observed in 
the thoracic outlet syndrome, small- and medium-sized ves-
sel vasculitis, polycythaemia, cryofibrynogenaemia, cold 
agglutinin disease, paraproteinaemia, vibration injury, and 
finally it can be provoked by drugs and toxins [1–4].
A number of haemostatic alterations have been reported 
in patients with RP, however mainly in those with its second-
ary form [2, 7, 8]. It has been suggested that endothelial cell 
activation and/or thrombosis in the digits could be involved 
in the pathogenesis of RP [1, 7]. Several reports demon-
strated that blood viscosity, along with plasma concentra-
tions of fibrinogen and gammaglobulins, were increased in 
RP subjects compared with healthy controls [8, 9]. Increased 
platelet activation has been reported in both primary and 
secondary RP associated with SSc [10]. Despite evidence for 
enhanced activation of the blood coagulation, to our knowl-
edge, there have been no clinical studies demonstrating that 
RP is linked to venous thromboembolism (VTE).
Stable fibrin clot formation is the final step of blood 
coagulation in vivo. It is known that fibrin clots composed 
of compact networks are less susceptible to lysis [11]. Such 
properties are characteristic for the so-called prothrombotic 
fibrin clot phenotype, usually driven by increased fibrinogen 
and thrombin formation, and have been identified in patients 
with coronary heart disease [12–15], ischemic stroke [16], 
and VTE [17, 18]. Furthermore, patients with rheumatoid 
arthritis, antiphospholipid syndrome and eosinophilic granu-
lomatosis with polyangiitis have also been found to display 
reduced plasma clot permeability and lysability [19–21]. No 
data on fibrin clot properties in subjects with RP have been 
published yet.
VTE is a common condition and its incidence rises with 
age [22]. The RP is not viewed as a risk factor for VTE. 
Therefore we evaluated the prevalence of RP among young 
and middle-aged VTE patients and tested the hypothesis 
that in such patients, similarly to other prothrombotic con-
ditions, this coexistence is associated with more pronounced 




In this prospective cohort study we recruited 360 consecu-
tive patients aged from 18 to 65 years with a history of deep 
vein thrombosis (DVT) or/and pulmonary embolism (PE) 
referred to the Center for Coagulation Disorders in Krakow, 
Poland, from June 2013 to March 2016.
Eligible patients had documented VTE treated with oral 
anticoagulants or low-molecular weight heparin for at least 3 
months prior to the enrolment. Exclusion criteria were signs 
of acute infection or known connective tissue disease, severe 
inherited thrombophilia, known malignancy, recent ischemic 
stroke or myocardial ischemia, chronic kidney disease stage 
III–V, liver injury, peripheral arterial disease, and haemato-
logical diseases known to be associated with RP.
The diagnosis of DVT and PE was established as 
described in the Electronic Supplementary Material. Demo-
graphic and clinical data were collected by a questionnaire. 
Raynaud’s phenomenon was established at least 6 months 
before VTE based on clinical features and nailfold capil-
laroscopy findings [23]. The study was approved by the 
Commission on Bioethics of the Regional Board of Medi-
cal Doctors in Krakow (No. 135/KBL/OIL/2013), and writ-
ten informed consent was obtained from all participants in 
accordance with the Declaration of Helsinki.
Laboratory investigations
Blood samples were drawn from an antecubital vein with 
minimal stasis. Detailed laboratory technics are described 
in the Electronic Supplementary Material.
Thrombophilia, including protein C, protein S, or 
antithrombin deficiency, factor V Leiden and prothrombin 
mutation G20210A, was tested as described [20]. Antinu-
clear antibodies (ANA) were identified using an immunoflu-
orescence method (Euroimmun, Lubeck, Germany). Positive 
results were defined by the presence of ANA at the 1:160 
serum dilution [24].
Serum levels of anticardiolipin antibodies (aCL) and anti-
β2-glycoprotein I antibodies (aβ2GPI) were measured by 
INOVA kits (San Diego, CA, USA). The aCL IgG ≥ 15 GPL 
and IgM ≥ 12.5 MPL were assumed as positive based on the 
cut-off values (the 99th percentile) established in healthy 
volunteers. Positive values for IgG and IgM aβ2GPI were 
≥ 20 SGU and SMU, respectively [25, 26]. Lupus antico-
agulant was determined using two coagulation assays as 
recommended [27].
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Fibrin permeation
Fibrin clot permeation was determined using a pressure-
driven system [11, 12]. Briefly, 20 mmol/L calcium chloride 
and 1 U/mL human thrombin (Sigma, St Louis, MO, USA) 
were added to 120 µL citrated plasma. A permeation coeffi-
cient  (Ks), which indicates the pore size, was calculated from 
the equation:  Ks= Q × L × η/t × A × Δp, where Q is the flow 
rate in time t; L, the length of a fibrin gel; η, the viscosity 
of liquid (in poise).
Lysis assays
Clot lysis time (CLT) was measured as described previously 
[28]. Briefly, citrated plasma was mixed with 15 mmol/L 
calcium chloride, 10,000-diluted human tissue factor 
(Innovin, Siemens) with a final concentration of 0.6 pM, 
12 µmol/L phospholipid vesicles and 60 ng/mL recombinant 
tissue plasminogen activator (Boehringer Ingelheim, Ingel-
heim, Germany). The turbidity was measured at 405 nm at 
37 °C. CLT was defined as the time from the midpoint of 
the clear-to-maximum-turbid transition to the midpoint of 
the maximum-turbid-to-clear transition.
Statistical analysis
The study was powered to have a 90% chance of detecting 
a 10% difference in CLT using a p-value of 0.05, based on 
the values of CLT as described previously [28]. In order to 
demonstrate such a difference or greater, 23 patients were 
required in each group.
Data are expressed as mean and standard deviation (SD) 
or as median (interquartile range, IQR) as appropriate. The 
Shapiro–Wilk test was used to assess conformity with a 
normal distribution. The continuous variables between 
two groups were compared using Student’s t-test and 
Mann–Whitney U-test as appropriate. Categorical variables 
were analysed using  Chi2 or Fisher’s exact test as appropri-
ate. The optimal cut-off points for fibrin clot parameters were 
evaluated by receiver operator characteristic curves (ROC). 
Pearson correlation coefficients were determined to assess 
associations between variables. Multiple linear regression 
analysis (the forward stepwise method) was used to deter-
mine predictors of clot variables. To evaluate independent 
predictors of the lowest  Ks < 6 × 10−9  cm2 and the longest 
CLT > 113 min, those values were grouped into quartiles 
based on the distribution in the whole population. These 
predictors were determined by multivariate logistic regres-
sion. Results were presented as odds ratios (ORs) with 95% 
confidence interval (CI) also after adjustment for fibrino-
gen. A two-sided p-value < 0.05 was considered statistically 
significant. Statistical analyses were performed with SPSS 
Statistic software and JMP®.
Results
Patient characteristics
As shown in Table A1, in the whole cohort the prevalence 
of RP was 17.5%. Positive aPL were found in 19 (5%) of 
VTE patients. After excluding patients with positive aPL, 
the final analysis included 341 patients, among them 57 
subjects with RP (17%). Positive ANA, mainly at a titre 
1:160, though without clinical signs of autoimmune dis-
eases, were observed in 141 patients, including 40 (28%) 
subjects diagnosed with RP. As expected, the prevalence 
of RP was 3.6-fold higher in women than in men.
Patients with RP did not differ from the remainder 
with regard to co-morbidities, the type of VTE (pro-
voked/unprovoked) or medications except for hypercho-
lesterolemia that was less common in the former group 
(Table A1). Most of the routine laboratory parameters, 
including hsCRP, were similar in the two groups, but we 
observed 11% higher fibrinogen and 16% higher vWF anti-
gen in patients with RP (Table A2).
When subjects with positive ANA were excluded, we 
found that in the ANA negative patients (n = 219), RP was 
associated with 29% higher plasma fibrinogen, 19% higher 
vWF and 15% higher platelet count. Serum hsCRP was 
doubled in the ANA negative patients with RP compared 
to those without RP (Table A3).
Comparative analysis of fibrinolysis activators and 
inhibitors for the whole group showed that TAFI, plas-
minogen, antiplasmin and PAI-1 levels were similar 
in patients with RP and those free of this phenomenon 
(Table A2). This also held true for RP patients with nega-
tive ANA (data not shown).
Fibrin clot properties
As shown in Table A2, patients with RP had 5% lower  Ks 
and 10% longer CLT compared with the remainder, indi-
cating the formation of denser plasma fibrin clots display-
ing impaired clot lysability. These differences remained 
significant after adjustment for fibrinogen (both p < 0.01). 
The separate analysis for women only (n = 195, 57.2%) 
showed that those with RP (n = 42, 12.3%) were charac-
terized by 6.6% lower  Ks, 11.2% longer CLT, and 18.5% 
higher vWF (all p < 0.05, Table A4). In the ANA negative 
subjects, RP was also associated with less favourable clot 
variables, as reflected by 8% lower  Ks, 14% longer CLT 
and 16% higher vWF (Table A3).
There were no associations of clot properties with 
demographics or clinical variables in the whole group. 
In subjects with RP (n = 57) fibrinogen and hsCRP were 
251Unfavourably altered plasma clot properties in patients with primary Raynaud’s phenomenon:…
1 3
inversely associated with  Ks (r = − 0.45, p = 0.0004, and 
r = − 0.42, p = 0.0012, respectively). A global fibrinolysis 
measure, CLT showed positive associations with PAI-1 
(r = 0.33, p = 0.012) and vWF (r = 0.35, p = 0.0072), but 
not with TAFI, plasminogen or antiplasmin. Receiver 
operator characteristic analysis (Fig. 1) showed good accu-
racy for  Ks and CLT to predict RP with the area under the 
curve (AUC) of 0.59 (95% CI 0.51–0.67) and 0.65 (95% CI 
0.57–0.73), respectively. To demonstrate the independent 
effect of continuous variables on fibrin clot properties, a 
multiple regression model with adjustment for fibrinogen 
was used. In the whole patient group, PAI-1 and HDL-C 
were independent predictors of  Ks, while the independent 
predictors of CLT were PAI-1 and vWF (Table 1).
The logistic regression analysis adjusted for fibrinogen 
showed that prolonged CLT, defined as the top quartile, 
CLT > 113 min, but not low  Ks was independently predicted 
by RP in both the whole patients group as well as this with 
negative ANA (OR 3.46, 95% CI 1.92–6.24, p < 0.001 and 
OR 5.89, 95% CI 2.32–14.94, p = 0.0002, respectively). 
Similar analysis for women only identified RP as an inde-
pendent predictor of CLT (OR 2.75, 95% CI 1.31–5.78, 
p = 0.0075). Moreover, hsCRP was an independent predictor 
of both the longest CLT and the lowest  Ks, regardless of the 
ANA status (Table 2). Prolonged CLT was also indepen-
dently predicted by vWF in both ANA positive and ANA 
negative groups (Table 2).
Discussion
This study is the first to demonstrate that primary RP is 
relatively common among young and middle-aged VTE 
patients, particularly among women, and this phenomenon 
Fig. 1  Receiver operating characteristic (ROC) curves for  Ks (a) and CLT (b). a Using RAYNAUD = ’1′ to be the positive level, AUC 0.59, 
95% CI 0.51–0.67; b using RAYNAUD = ‘1’ to be the positive level, AUC 0.65, 95% CI 0.57–0.73
Table 1  Independent predictors of fibrin clot properties
Variable Estimate (95% confidence interval) p-Value
Predictors of  Ks
 PAI-1, ng/mL − 0.03 (− 0.05; − 0.007) 0.01
 HDL-C, mmol/L 0.19 (0.004; 0.38) 0.04
Predictors of CLT
 PAI-1, ng/mL 1.03 (1.01; 1.37) < 0.001
 vWF, % 0.10 (0.08; 0.14) < 0.001
Table 2  Independent predictors of the lowest  Ks and the longest CLT
Variable Lower 95% Upper 95% p-Value
Predictors of  Ks
 Q1  Ks ANA positive (n = 341)
  hsCRP 1.05 1.20 0.0008
 Q1  Ks ANA negative
  hsCRP 1.06 1.27 0.0016
Predictors of CLT
 Q4 CLT ANA positive
  hsCRP 0.85 0.98 0.046
  vWF antigen 1.01 1.02 < 0.0001
 Q4 CLT ANA negative
  hsCRP 1.00 1.18 0.041
  vWF antigen 1.01 1.02 < 0.0001
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is characterized by unfavourably altered plasma fibrin clot 
properties. We showed that plasma clots of patients suffer-
ing from primary RP display smaller pores and are degraded 
at a slower rate. Thus, the prothrombotic plasma clot phe-
notype may contribute to the pathogenesis of primary RP 
and increase the risk of thrombosis. Primary RP is a novel 
condition in which unfavourable fibrin alterations were dem-
onstrated and they have been shown to be potent enough to 
be detectable following the VTE episode, which might per 
se enhance blood coagulation. It remains to be established 
whether similar clot characteristics can be demonstrated in 
primary RP prior to thrombotic events.
To our knowledge, this study is the first to evaluate asso-
ciations of primary RP with thrombosis in patients who 
experienced provoked or unprovoked VTE. The prevalence 
of RP in our study performed in subjects aged 65 years or 
less was relatively high when compared to the most pop-
ulation-based surveys in which the estimated prevalence 
of RP is 3–5% [1]. This indicates that primary RP cases 
are overrepresented among VTE patients. In the literature, 
there is evidence linking RP with cardiovascular diseases, 
including arterial thromboembolic events, as demonstrated 
by Garner at al. in a systematic review of observational stud-
ies on primary RP [29]. An association of primary RP and 
cardiovascular diseases, including cardiovascular mortality, 
has also been reported [30, 31]. Nietert et al. suggested that 
RP might be a sign or precursor of undiagnosed vascular 
disease [31]. It might be speculated that RP is a risk factor 
for VTE of particular value among young and middle-aged 
women. However, a larger study on patients with primary 
RP is needed to validate this intriguing concept.
Clots more resistant to lysis with reduced permeability 
have already been described in several diseases associated 
with increased risk of arterial and/or venous thromboem-
bolic events [13–20]. Our novel finding is that the coexist-
ence of RP and VTE renders fibrin clots more prothrom-
botic, namely denser and more resistant to lysis compared 
with clot features observed in patients without this disorder. 
Although the differences are small, they are statistically sig-
nificant also after adjustment for fibrinogen, a major deter-
minant of fibrin clot features. Recent data have reported 
similar alterations in some systemic autoimmune conditions 
[19–21]. However, we found the impact of primary RP also 
when patients with positive ANA status were ruled out. The 
current study indicates that primary RP is an additional dis-
order associated with prothrombotic clot alterations. It might 
be hypothesized that prothrombotic mechanisms observed 
in VTE patients which are more pronounced in those with 
coexisting RP, might predispose to recurrent thrombotic 
events in this subset of patients.
Determinants of the prothrombotic clot phenotype 
observed in patients with RP are likely multiple and in 
part similar to other conditions [32]. It is to some extent 
driven by inflammatory changes associated with increased 
fibrinogen and CRP observed in the current RP patients. It 
has been demonstrated that CRP binds to fibrinogen and is 
associated with the formation of denser and more resist-
ant to lysis fibrin clots [33]. We observed similar inverse 
associations of clot permeability with CRP concentrations, 
as reported in cardiovascular patients [13], which supports 
contribution of elevated CRP to plasma clot features. 
Moreover, the current study provides additional evidence 
for a role of an inflammatory state in unfavourable fibrin 
properties, reaching beyond the effect of elevated fibrino-
gen, since the differences between groups in fibrin clot 
characteristics remained significant after adjustment for 
this confounder.
Importantly, we found increased levels of circulating 
vWF in VTE patients with RP, suggesting an important 
contribution of endothelial cells activation and/or injury 
in this disease. Most published reports showed normal 
vWF plasma levels in patients with primary RP, while in 
subjects with secondary RP, these concentrations were sig-
nificantly higher [34]. Elevated vWF has been shown to be 
associated with the generation of monocyte-and endothe-
lial cell-derived microparticles, which might negatively 
affect clot features and modulate inflammation, blood 
coagulation and vascular function [35, 36]. It is also possi-
ble that increased vWF in patients with primary RP could 
identify the subjects at higher risk of developing an auto-
immune systemic disease. In a recent observational study 
on 82 patients with RP, Gualtierotti et al. demonstrated 
higher levels of endothelial damage markers, including 
vWF, in subjects who subsequently developed a connec-
tive tissue disease, suggesting that vWF could predict such 
a progression towards a systemic disease [37]. This specu-
lation needs a large-scale study with long-term follow-up.
The study has several limitations. First, the sample 
size was relatively limited, however, analyses were suf-
ficiently powered and it is unlikely that the differences 
reported here result from a significant recruitment bias. 
Second, it was a cross-sectional study and our analysis 
was based on a determination of each variable at a single 
time point, therefore some changes in fibrin characteristics 
over time could be observed. Moreover, assessment of the 
same parameters prior to the VTE episode in a cohort of 
subjects with primary RP is needed to elucidate a role of 
altered fibrin features in this disorder. Prospective stud-
ies are required to assess the impact of RP on recurrent 
VTE, which might confirm its relevance as a new VTE 
risk factor. Our findings cannot be likely extrapolated after 
the first episode. Finally, we did not evaluate thrombin 
generation in this study, however previous reports failed 
to demonstrate increased thrombin formation in RP [38].
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Conclusions
This study shows that patients with primary RP have the 
prothrombotic clot phenotype at least in part associated 
with enhanced endothelial damage and inflammatory state. 
It might be speculated that the presence of RP may predis-
pose to thromboembolic episodes given a high prevalence 
of this vascular disorder among VTE patients, particularly 
among young and middle-aged women. Further studies are 
required to elucidate clinical relevance of altered fibrin 
clot properties in the context of thrombotic risk among 
patients with various forms of RP.
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